What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Alzheimer's disease, Parkinson's disease, and mild cognitive impairment (non-diabetic) (n=1260). Intervention: GLP-1 receptor agonists vs. Placebo or standard care. Primary outcome: Global cognition (SMD 0.14, 95% CI 0.01 to 0.27, p=0.04).

What question did this study set out to answer?

This analysis aims to evaluate the effects of GLP-1 receptor agonists on cognition, biomarkers, and clinical outcomes in non-diabetic individuals with Alzheimer's and Parkinson's diseases.

May 9, 2026Archives of Pharmacal ResearchOpen Access

Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Key result

GLP-1RAs marginally improve global cognition versus control but fail to provide clinically important benefit.

SMD 0.14
95% CI 0.01 to 0.27
P=0.04
n=1,260

Why the study?

GLP-1 receptor agonists are promising for Alzheimer's and Parkinson's diseases, but their effects in non-diabetic populations, independent of metabolic confounding, remain unclear.

Do GLP-1RAs improve cognition and clinical outcomes in non-diabetic individuals with Alzheimer's disease, Parkinson's disease, and mild cognitive impairment?

Comparison

GLP-1RAs vs control

Design

Systematic review and random-effects meta-analysis

Authors

YEYomna ElghanamChung-Ang University EKEunyoung KimChung-Ang University

Discussion

Member takes

Implication

Does not support routine GLP-1RA use for cognition; leaves open therapeutic relevance pending larger dedicated trials.

Key Points

This analysis aims to evaluate the effects of GLP-1 receptor agonists on cognition, biomarkers, and clinical outcomes in non-diabetic individuals with Alzheimer's and Parkinson's diseases.
Systematic review and meta-analysis of studies from PubMed, Embase, and Web of Science.
Fourteen randomized controlled trials with a total of 1260 participants were included.
Random-effects meta-analysis calculated standardized mean differences, mean differences, and risk ratios with 95% confidence intervals.
GLP-1 receptor agonists showed a small improvement in global cognition (SMD 0.14, 95% CI 0.01 to 0.27), but this was not clinically meaningful.
In the PD subgroup, GLP-1RAs significantly improved depression symptoms (MD − 2.09, 95% CI − 3.99 to − 0.20), yet below clinically important benefit thresholds.
GLP-1RAs were associated with poorer tolerability and increased gastrointestinal adverse events.

Study Design

Type

Meta-Analysis (n=1,260)

Structured PICO

Do GLP-1RAs improve cognition and clinical outcomes in non-diabetic individuals with Alzheimer's disease, Parkinson's disease, and mild cognitive impairment?

Population

14 RCTs enrolling 1260 non-diabetic individuals with Parkinson's disease (PD), Alzheimer's disease (AD), and mild cognitive impairment

Intervention

Glucagon-like peptide-1 receptor agonists (GLP-1RAs)

Comparator

Control

Outcome

Global cognition, clinical outcomes, biomarkers, and safety assessed using minimal clinically important difference thresholds

Main Result

Effect estimate: SMD 0.14 (95% CI 0.01 to 0.27)

p-value: p=0.04

Current evidence does not support a clinically meaningful benefit of GLP-1RAs for cognitive or clinical outcomes in non-diabetic patients with Alzheimer's or Parkinson's disease.

Limitations

Biomarker findings were inconsistent across trials.
Adverse effects, particularly gastrointestinal events and poorer tolerability, may limit clinical utility.
Some included trials had missing outcome data, deviations from intended interventions, and baseline imbalances.
Pooling of cognitively distinct measures under broad constructs may complicate construct validity and clinical interpretability.

Cite This Study

Elghanam et al. (2026) conducted a meta-analysis in Alzheimer's disease, Parkinson's disease, and mild cognitive impairment (non-diabetic) (n=1,260). GLP-1 receptor agonists vs. Placebo or standard care was evaluated on Global cognition (SMD 0.14, 95% CI 0.01 to 0.27, p=0.04). GLP-1 receptor agonists showed a small statistically significant improvement in global cognition (SMD 0.14) compared to control, but with only a 1% probability of a clinically important benefit.

synapsesocial.com/papers/69fecfe9b9154b0b82876f15 https://doi.org/10.1007/s12272-026-01615-y

Topics

GLP-1 agonists cardiovascular outcomes Retatrutide GLP-1 receptor agonists

View Full Paper

Ask AI

Bookmark

Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Topics

Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Topics

Also Consider